(S1 (S (NP (NP (NP (JJ Vasoactive) (NNS effects)) (PP (IN of) (NP (NN methylamine))) (PP (IN in) (NP (VBN isolated) (JJ human) (NN blood) (NNS vessels)))) (: :) (NP (NP (NN role)) (PP (IN of) (NP (NP (JJ semicarbazide-sensitive) (NN amine) (NN oxidase)) (, ,) (NP (NN formaldehyde)) (, ,) (CC and) (NP (NN hydrogen) (NN peroxide))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NP (NN methylamine)) (PRN (-LRB- -LRB-) (NP (NN MA)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ semicarbazide-sensitive) (NN amine) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NN SSAO)) (-RRB- -RRB-))) (NN activity))) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ cardiovascular) (NNS complications)) (PP (IN in) (NP (JJ human) (NNS diabetics)))))))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT this))))) (, ,) (NP (PRP we)) (VP (LST (LS 1) (-RRB- -RRB-)) (VBD determined) (NP (NP (DT the) (JJ acute) (JJ vasoactive) (NNS effects)) (PP (IN of) (NP (NP (NN MA)) (PRN (-LRB- -LRB-) (NP (CD 1-1,000) (NN micromol/l)) (-RRB- -RRB-)))) (PP (IN in) (S (S (NP (NP (ADJP (JJ uncontracted) (S (S (CC and) (NN norepinephrine) (-LRB- -LRB-) (NN NE) (: ;) (CD 1) (NN micromol/l) (-RRB- -RRB-) (NP (JJ -precontracted) (JJ human) (NN blood) (NNS vessels)) (VP (VBN used) (PP (IN for) (NP (NP (JJ coronary) (NN artery) (VB bypass) (NNS grafts)) (PRN (-LRB- -LSB-) (NP (NP (NP (NP (JJ left) (JJ internal) (JJ mammary) (NN artery)) (PRN (-LRB- -LRB-) (NP (NN LIMA)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ radial) (NN artery)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ right) (JJ saphenous) (NN vein))) (PRN (-LRB- -LRB-) (NP (NN RSV)) (-RRB- -RRB-))) (-RRB- -RSB-)))))) (: ;) (LST (LS 2) (-RRB- -RRB-))))) (VP (VBN tested) (SBAR (IN whether) (S (S (NP (NP (JJ MA) (NNS effects)) (PP (IN in) (NP (NP (NN LIMA)) (CC and) (NP (NN RSV))))) (VP (VBD were) (ADJP (JJ dependent) (PP (IN on) (NP (NN SSAO) (NN activity)))) (S (VP (VBG using) (NP (NP (DT the) (NN SSAO) (NN inhibitor) (NN semicarbazide)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mmol/l)) (, ,) (NP (CD 15) (NN min)) (-RRB- -RRB-))))))) (: ;) (S (LST (LS 3) (-RRB- -RRB-)) (VP (VBD determined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (CD MA) (NNS metabolites) (NN formaldehyde)) (CC and) (NP (NN hydrogen) (NN peroxide)))) (PP (IN in) (NP (NP (NN LIMA)) (CC and) (NP (NN RSV))))))) (: ;) (S (LST (LS 4) (-RRB- -RRB-)) (VP (VBD tested) (SBAR (IN whether) (S (NP (DT the) (NN MA) (NN response)) (VP (VBD was) (ADJP (NP (NP (JJ nitric) (NN oxide)) (, ,) (NP (NN prostaglandin)) (, ,) (CC or) (NP (NN hyperpolarization))) (JJ dependent)))))))))) (: ;) (CD 5) (-RRB- -RRB-)) (VP (VBD measured) (NP (DT the) (NN LIMA) (CC and) (NN RSV) (NN cGMP) (NNS levels)) (PP (IN after) (NP (NN MA) (NN exposure))))) (: ;) (CC and) (S (NP (CD 6) (-RRB- -RRB-)) (VP (VBN quantified) (NP (NP (NN SSAO) (NN activity)) (PP (IN in) (NP (NP (NN LIMA)) (, ,) (NP (NN RA)) (, ,) (CC and) (NP (NN RSV))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ NE-precontracted) (NNS vessels))) (, ,) (NP (NN MA)) (VP (VBD stimulated) (NP (NP (NP (DT a) (JJ biphasic) (NN response)) (PP (IN in) (NP (NP (NP (NN RA)) (CC and) (NP (NN RSV))) (PRN (-LRB- -LRB-) (NP (NP (JJ rapid) (NN contraction)) (VP (VBN followed) (PP (IN by) (NP (JJ prolonged) (NN relaxation))))) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ dominant) (NN relaxation)) (PP (IN in) (NP (NN LIMA))))) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (CC +/-) (NP (NN SE))) (, ,) (NP (NN %) (NN relaxation)) (: :) (NP (CD 55.4) (CC +/-) (CD 3.9)) (, ,) (S (NP (NN n)) (VP (JJ =) (NP (CD 30)))) (-RRB- -RRB-))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ MA-induced) (NN relaxation)) (PP (IN in) (NP (NN LIMA)))) (VP (VBD was) (ADJP (ADJP (JJ repeatable)) (, ,) (ADJP (JJ nontoxic)) (, ,) (CC and) (ADJP (NN age) (JJ independent))))) (. .)))
(S1 (S (S (NP (NN Semicarbazide)) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NP (JJ MA-induced) (NN relaxation)) (PRN (-LRB- -LRB-) (NP (NN %) (NN inhibition)) (: :) (S (NP (QP (CD 82.5) (CC +/-) (CD 4.8)) (, ,) (NN n)) (VP (JJ =) (NP (CD 7)))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ SSAO) (NN activity)) (PRN (-LRB- -LRB-) (NP (NN %) (NN inhibition)) (: :) (S (NP (QP (CD 98.1) (CC +/-) (CD 1.3)) (, ,) (NN n)) (VP (JJ =) (NP (CD 26)))) (-RRB- -RRB-)))) (PP (IN in) (NP (NN LIMA))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NN Formaldehyde)) (PRN (-LRB- -LRB-) (NP (NN %) (NN relaxation)) (: :) (NP (CD 37.3) (CC +/-) (CD 18.6)) (, ,) (NP (NN n) (JJ =) (CD 3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN H-LRB-2-RRB-O-LRB-2-RRB-)) (PRN (-LRB- -LRB-) (NP (NN %) (NN relaxation)) (: :) (NP (CD 55.6) (CC +/-) (CD 9.0)) (, ,) (NP (NN n) (JJ =) (CD 9)) (-RRB- -RRB-)))) (PP (IN at) (NP (CD 1) (NN mmol/l)))) (VP (VBD relaxed) (NP (NP (JJ NE-precontracted) (NN LIMA)) (ADJP (JJ comparable) (PP (IN with) (NP (NN MA))))))) (. .)))
(S1 (S (S (NP (NP (JJ MA-induced) (NN relaxation)) (PP (IN in) (NP (NN LIMA)))) (VP (VBD was) (UCP (ADJP (NP (NP (JJ nitric) (NN oxide)) (, ,) (NP (NN prostaglandin)) (, ,) (CC and) (ADVP (RB possibly)) (NP (NN cGMP))) (JJ independent)) (CC and) (VP (VBN blocked) (PP (IN by) (NP (NN hyperpolarization))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ vascular) (NN SSAO) (NN activity)) (VP (MD may) (VP (VBP convert) (NP (JJ endogenous) (NNS amines)) (, ,) (PP (IN like) (NP (NN MA))) (, ,) (PP (TO to) (NP (JJ vasoactive) (NNS metabolites))))))))) (. .)))
